BlackRock trims Hensoldt voting rights to 4.96% from 4.99%
Reuters2026/08/28 08:39- BlackRock trimmed its total voting rights in Hensoldt to 4.96% from 4.99%, crossing the 5% threshold on Aug. 25.
- Equity stake fell to 1.93% from 3.18%.
- Instruments position rose to 3.03% from 1.81%, led by lent securities at 2.97% and contracts for difference at 0.06%.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like

Spot bitcoin ETFs pull in $987 million last week as institutional demand recovers
Silver Price Forecast: XAG/USD dips below $66.00 and hints at a bearish “H&S”
Twice thwarted in a week! Novartis (NVS.US) fails in phase III trial for blockbuster heart disease drug, stock plummets; Amgen (AMGN.US) dragged down as well
Swiss pharmaceutical giant Novartis has suffered another clinical trial setback—within one week, the company’s second major drug candidate has failed in a late-stage study. This latest disappointment concerns its potential blockbuster heart disease drug pelacarsen.
